News Releases

News & Resources

News Releases

Ellen Morgan Becomes Chairman of the Board at Synteract

SAN DIEGO – March 2, 2011 – Synteract, Inc., a full-service, global contract research organization (CRO) dedicated to meeting the clinical research needs of biotechnology, medical device, and pharmaceutical companies, announced a change in position for Ellen Morgan, co-founder, who has served as president and CEO of the company since its inception in 1995. Effective March 31, Morgan will become chairman of the board for the company and will continue to help grow the business on a part-time basis. 

To provide continuity while a search is conducted for a new president and CEO, the company will be headed on an interim basis by Stewart Bieler, COO, who will report directly to the board of directors. Bieler has been with Synteract since 1999, and has been instrumental in the growth of Synteract as a full-service clinical CRO.

Morgan said, “I’m so appreciative to have had the opportunity to work on a daily basis for the past 16 years with the most talented and dedicated group of individuals in the industry. I am confident that the team will continue to provide the same responsive, flexible service to our clients that we have become known for, while I look forward to serving the company in a more traditional chairman’s role and gaining the time to pursue additional interests and commitments.” 

Synteract, which prides itself on being a “CRO with Character” focusing on responsiveness and integrity, has a great repeat business track record (greater than 90 percent repeat and referral) due to the quality of its work and strong customer service. From its beginnings as a 2-person company in 1995, it has grown to become an international, multi-million dollar company with more than 350 staff. 

Nick Orum, president of Gryphon Investors, said, “Gryphon has been privileged to work with Ellen over the past few years and looks forward to her continued leadership as chairman of the board.” 

About Synteract 
Synteract is a privately-held, full-service contract research organization, serving clinical trial needs of biotechnology, medical device, and pharmaceutical companies. Synteract provides high quality, customized service, working closely with drug and device sponsors. Headquartered in California, with offices in North Carolina and Czech Republic, Synteract offers clinical expertise in multiple therapeutic areas, including a strong emphasis in oncology, central nervous system (CNS), cardiovascular, respiratory, and ophthalmology. Information: http://www.synteract.com; (760) 268.8200. 

CONTACTS: 
Beth Walsh 
beth@clearpointagency.com 
858-724-2500

x

Contact Synteract

Tell us how to stay in touch with you:

*Required